Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14310266 | 0.90 | HDAC6 (0.38) | KDM4EALDH1A1RXFP1HDAC3HDAC4 | |
| SCHEMBL1601903 | 0.90 | KDM4E (0.46) | KDM4EALDH1A1RXFP1HDAC3HDAC4 | |
| SCHEMBL1602945 | 0.82 | KDM4E (0.47) | KDM4EALDH1A1RXFP1HDAC3HDAC4 | |
| SCHEMBL1602615 | 0.81 | HDAC3 (0.46) | KDM4EALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL1603042 | 0.81 | HDAC3 (0.46) | KDM4EALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL14320072 | 0.80 | KDM4E (0.45) | KDM4EALDH1A1RXFP1HDAC3HDAC4 | |
| SCHEMBL1602723 | 0.80 | HDAC3 (0.48) | KDM4EALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL1602018 | 0.79 | HDAC3 (0.46) | KDM4EALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL1603167 | 0.79 | HDAC3 (0.46) | KDM4EALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL1602962 | 0.78 | ALDH1A1 (0.48) | KDM4EALDH1A1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919488-B2 | Therapeutic compounds | PFIZER INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919488-B2 | Therapeutic compounds | PFIZER INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919488-B2 | Therapeutic compounds | PFIZER INC. (US) | 2011-04-05 | — | — | US | disclosed |
| CN-101511812-A | Pyrazole derivatives as cytochrome P450 inhibitors | PFIZER PROD INC (US) | 2009-08-19 | — | — | CN | disclosed |
| EP-2046774-A1 | PYRAZOLE DERIVATIVES AS CYTOCHROME P450 INHIBITORS | Pfizer Products Inc. (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080021011-A1 | THERAPEUTIC COMPOUNDS | PFIZER INC | 2008-01-24 | — | — | US | disclosed |
| US-20080021011-A1 | THERAPEUTIC COMPOUNDS | PFIZER INC | 2008-01-24 | — | — | US | disclosed |
| US-20080021011-A1 | THERAPEUTIC COMPOUNDS | PFIZER INC | 2008-01-24 | — | — | US | disclosed |
| WO-2008004096-A1 | PYRAZOLE DERIVATIVES AS CYTOCHROME P450 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021011-A1 | THERAPEUTIC COMPOUNDS | SLC10A1, PCSK9, CFTR | KDM4E 3896/4885ALDH1A1 310/4885RXFP1 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.